ETON · Eton Pharmaceuticals, Inc.
$58.86
+18.06 (+44.26%)
At close · Aug 14
Market Cap
$1.68B
Shares
28.58M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-06-26 | Gruber James R. | Officer | 251,818 | 2026-06-26 | Raymond James & Associates |
| 2026-06-25 | Gruber James R. | Officer | 25,000 | 2026-06-25 | Raymond James & Associates |
| 2026-06-23 | Gruber James R. | Officer | 25,000 | 2026-06-23 | Raymond James & Associates |
| 2026-06-17 | Adams Jennifer McKie | Director | 50,000 | 2026-06-17 | Raymond James & Associates |
| 2026-06-02 | Gruber James R. | Officer | 3,117 | 2026-06-02 | Raymond James & Associates |
| 2026-05-28 | BRYNJELSEN SEAN | Director | 120,000 | 2026-05-28 | The Charles Schwab Corporation |
| 2026-05-22 | Krempa David | Officer | 100,000 | 2026-05-22 | Raymond James & Associates, Inc. |
| 2026-01-14 | BRYNJELSEN SEAN | Officer, Director, 10% Stockholder | 5,015 | 2026-01-14 | RAYMOND JAMES & ASSOCIATES |
| 2026-01-14 | Krempa David | Officer | 1,942 | 2026-01-14 | Raymond James & Associates |
| 2026-01-14 | Gruber James R. | Officer | 2,293 | 2026-01-14 | Raymond James & Associates |
| 2025-12-12 | Gruber James R. | Officer | 5,450 | 2025-12-12 | Raymond James & Associates |
| 2025-12-12 | BRYNJELSEN SEAN | Officer, Director, 10% Stockholder | 8,035 | 2025-12-12 | Raymond James & Associates |
| 2025-12-12 | Erdogan-Trinkaus Ipek | Officer | 99 | 2025-12-12 | Raymond James & Associates |
| 2025-12-12 | Krempa David | Officer | 7,545 | 2025-12-12 | Raymond James & Associates |
| 2025-08-19 | Gruber James R. | Officer | 41,713 | 2025-08-18 | Raymond James & Associates |
| 2025-06-12 | Krempa David | Officer | 40,000 | 2025-06-12 | Raymond James & Associates |
| 2025-06-03 | BRYNJELSEN SEAN | Officer, Director, 10% Stockholder | 210,000 | 2025-06-03 | Raymond James & Associates |
Showing 1–17 of 17 filings
Key facts
CIK
1710340
CUSIP
29772L108
13F (30d)
156 filings
154 filers
Visit website
Investor relations